Cargando…

Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma

Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor-I activation, currently under clinical trial in a variety of cancers. We have tested the combined effects of galunisertib- and interleukin-15-activated dendritic cells in an aggressive and highly metastatic murine lympho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hira, Sumit Kumar, Rej, Abhinandan, Paladhi, Ankush, Singh, Ranjeet, Saha, Jayasree, Mondal, Indrani, Bhattacharyya, Sankar, Manna, Partha Pratim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559877/ https://www.ncbi.nlm.nih.gov/pubmed/33089111 http://dx.doi.org/10.1016/j.isci.2020.101623

Ejemplares similares

Nanoscale Diamond-Based Formulation as an Immunomodulator and Potential Therapeutic for Lymphoma
por: Paladhi, Ankush, et al.
Publicado: (2022)

Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity
por: Paladhi, Ankush, et al.
Publicado: (2022)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

PGC1 alpha coactivates ERG fusion to drive antioxidant target genes under metabolic stress
por: Dhara, Aiindrila, et al.
Publicado: (2022)

Targeted Delivery of Doxorubicin-Loaded Poly (ε-caprolactone)-b-Poly (N-vinylpyrrolidone) Micelles Enhances Antitumor Effect in Lymphoma
por: Hira, Sumit Kumar, et al.
Publicado: (2014)

Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host
por: Singh, Ranjeet, et al.
Publicado: (2023)

Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
por: Zhang, Chao, et al.
Publicado: (2016)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression
por: Rani, Bhavna, et al.
Publicado: (2018)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

Cysticerci Drive Dendritic Cells to Promote In Vitro and In Vivo Tregs Differentiation
por: Adalid-Peralta, Laura, et al.
Publicado: (2013)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Galunisertib-Loaded Gelatin Methacryloyl Hydrogel Microneedle Patch for Cardiac Repair after Myocardial Infarction
por: Chen, Haiting, et al.
Publicado: (2022)

Temporal resolution in fluorescence imaging
por: Mondal, Partha Pratim
Publicado: (2014)

Probabilistic Optically-Selective Single-molecule Imaging Based Localization Encoded (POSSIBLE) microscopy for ultra-superresolution imaging
por: Pratim Mondal, Partha
Publicado: (2020)

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2020)

Design of Gelatin-Capped Plasmonic-Diatomite Nanoparticles with Enhanced Galunisertib Loading Capacity for Drug Delivery Applications
por: Tramontano, Chiara, et al.
Publicado: (2021)

Roy et al. On Two Novel Parameters for Validation of Predictive QSAR Models. Molecules, 2009, 14, 1660-1701
por: Roy, Partha Pratim, et al.
Publicado: (2010)

On Two Novel Parameters for Validation of Predictive QSAR Models
por: Pratim Roy, Partha, et al.
Publicado: (2009)

Downregulated TNF-α Levels after Cryo-Thermal Therapy Drive Tregs Fragility to Promote Long-Term Antitumor Immunity
por: Lou, Yue, et al.
Publicado: (2021)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl(4)-Induced Liver Fibrosis in Rats
por: Panzarini, Elisa, et al.
Publicado: (2022)

Fundamentals of fluorescence microscopy: exploring life with light
por: Mondal, Partha Pratim, et al.
Publicado: (2014)

Simultaneous multilayer scanning and detection for multiphoton fluorescence microscopy
por: Mondal, Partha Pratim, et al.
Publicado: (2011)

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
por: Jank, Bernhard J., et al.
Publicado: (2022)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
por: Nadal, Ernest, et al.
Publicado: (2023)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats
por: Liu, X., et al.
Publicado: (2016)

Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression
por: Donnelly, Conor, et al.
Publicado: (2018)

Prevalence of Ischemic Heart Disease Among Urban Population of Siliguri, West Bengal
por: Mandal, Sukanta, et al.
Publicado: (2009)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice
por: Park, Jeong-Ho, et al.
Publicado: (2020)

Spatial Filter Based Bessel-Like Beam for Improved Penetration Depth Imaging in Fluorescence Microscopy
por: Purnapatra, Subhajit B., et al.
Publicado: (2012)

Three Dimensional Fluorescence Imaging Using Multiple Light-Sheet Microscopy
por: Mohan, Kavya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_poe6fiv0av29ecgauolal1gbdm